COST ANALYSIS OF PATIENTS WITH SQUAMOUS CELL CERVICAL CANCER STAGE IIB-IIIB WITH PACLITAXEL CISPLATIN CHEMOTHERAPY FROM THE SOCIETAL PERSPECTIVE. (2023). Journal Pharmaceutical Science and Application, 5(1), 34-44. https://doi.org/10.24843/JPSA.2023.v05.i01.p05